IL2 and acute myeloid leukemia: Clinical trials using infusions of IL-2-activated haploidentical NK cells in AML patients showed encouraging results with in vivo expansions of donor NK cells and complete remissions (CR) in certain patients, suggesting an antitumor NK-cell-mediated immune response (72, 73).